Bristol-Myers Squibb Co. (BMY)

47.30
NYSE : Health Technology
Prev Close 47.74
Day Low/High 46.89 / 47.64
52 Wk Low/High 44.30 / 63.69
Avg Volume 18.43M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 78.09B
EPS 3.00
P/E Ratio 15.20
Div & Yield 1.64 (3.42%)
Dow Drops More Than 600 Points on Apple Warning, China Fears

Dow Drops More Than 600 Points on Apple Warning, China Fears

All three major indices dropped more than 2% Thursday.

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Video: Jim's Daily Rundown for Thursday

Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.

Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale Of Celgene Corporation; Are Celgene Shareholders Getting A Fair Deal?

Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale Of Celgene Corporation; Are Celgene Shareholders Getting A Fair Deal?

SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Celgene Corporation (NASDAQ: CELG) ("Celgene") breached their fiduciary duties in connection with the...

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb (NYSE:BMY) today announced EPS guidance for full-year 2019.

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co.

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients...

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to...

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences' VE800,...

Bristol-Myers Squibb Announces Dividend Increase

Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb Company (NYSE: BMY) today announced it will transfer $3.8 billion of U.

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 19 data presentations and publications, including two oral presentations, from Company-sponsored studies and collaborations evaluating Opdivo (nivolumab), Sprycel (dasatinib) and Empliciti...

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York.

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Shares decline after the company says a lung-cancer study it had been working on failed.

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -451 study did not meet its primary endpoint of overall survival (OS) with Opdivo (nivolumab) 1 mg/kg in combination with Yervoy (ipilimumab) 3 mg/kg versus placebo as a...

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that ReviveMed and Strand Therapeutics are the winners of Bristol-Myers...

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, in Boston.

TheStreet Quant Rating: C+ (Hold)